TheraRadar
← Back
Data updated: Jun 28, 2026

ANTHEA PHARMA

Generics

ANTHEA PHARMA is a generic drug manufacturer focused on Cardiovascular, Metabolic, Gastroenterology.

2025
Since
7
Drugs
-
Trials
0
New Drugs (2yr)

ANTHEA PHARMA's Key Drugs

ANTHEA PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ANTHEA PHARMA's Recent FDA Approvals

New NDA/BLA approvals for ANTHEA PHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ANTHEA PHARMA's Therapeutic Areas

ANTHEA PHARMA's approved drugs and pipeline span 3 therapeutic areas, led by Cardiovascular and Metabolic. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 50%
2 drugs
Metabolic 25%
1 drugs
Gastroenterology 25%
1 drugs

ANTHEA PHARMA's Top Competitors

ANTHEA PHARMA's closest competitors by therapeutic-area and drug-target overlap include Takeda, Amgen, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ANTHEA PHARMA Pipeline Snapshot

Active clinical trials for ANTHEA PHARMA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling